Market Research Report
Investigation Report on China's Tacrolimus Market 2021-2025
|Published by||China Research and Intelligence||Product code||1002611|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Tacrolimus Market 2021-2025|
|Published: April 23, 2021||Content info: 50 Pages||
Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and the injection are used to prevent graft rejection after liver or kidney transplantation. In recent years, Tacrolimus has become the first-line medication for liver and kidney transplantation. The Tacrolimus eye drop is used for vernal keratoconjunctivitis with poor anti-allergic treatment.
Tacrolimus' original drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.
According to CRI's market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% in 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020. The growth rate in 2020 was 4.8% Year on Year, which slowed down compared to that in the previous years due to the COVID-19 epidemic.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Tacrolimus will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. In light of research findings, the indication for preventing rejection in transplantation operations generates most sales for Tacrolimus. However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means the demand for transplantation is not satisfied. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for Tacrolimus.